Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 16/20 | 0.69 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407333 | 0.91 | ENPP1 (0.74) | ENPP1ENPP3CA12CA1CA2 | |
| SCHEMBL20782623 | 0.88 | ENPP1 (0.69) | ENPP1ENPP3NR3C1PGR | |
| SCHEMBL20770893 | 0.82 | ENPP1 (1.00) | ENPP1ENPP3CA12CA1CA2 | |
| SCHEMBL30105952 | 0.82 | ENPP1 (1.00) | ENPP1ENPP3CA12CA1CA2 | |
| SCHEMBL22407559 | 0.81 | ENPP1 (0.72) | ENPP1ENPP3CA12CA1CA2 | |
| SCHEMBL20782441 | 0.78 | ENPP1 (0.71) | ENPP1ENPP3 | |
| SCHEMBL22407352 | 0.77 | ENPP1 (0.86) | ENPP1ENPP3CA12CA1CA2 | |
| SCHEMBL20782586 | 0.76 | ENPP1 (0.54) | ENPP1ENPP3 | |
| SCHEMBL30446173 | 0.76 | ENPP1 (0.54) | ENPP1ENPP3 | |
| SCHEMBL20782860 | 0.76 | ENPP1 (0.71) | ENPP1ENPP3NR3C1PGRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885ENPP3 2/4885NR3C1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.